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The initiation, progression, and metastasis of tumors involve not only cancer cells, but
also the tumor microenvironment, which consists of immune or inflammatory cells,
fibroblasts, endothelial cells, and extracellular matrix components (ECM). Fibroblasts are
ubiquitous stromal cells that can influence other neighboring cell types through the
secretion of chemokines, cytokines, ECM, ECM remodeling enzymes, and other
metabolites. Myofibroblasts are a distinct subtype of fibroblasts characterized by
expression α-smooth muscle actin (αSMA). These cells are a dominant component of the
microenvironment, and a FSP1 and FAP could be a different clone of fibroblasts.
Myofibroblasts also have been known to contribute to cancer progression and metastasis
in multiple cancer types including breast and pancreas cancer, both of which are
associated with extensive desmoplasia. However, the role of αSMA+ myofibroblasts in
the context of colorectal cancer has remained largely descriptive and functionally
unknown. The studies outlined in this project explored the functional contribution of
αSMA+ myofibroblasts in the disease progression of colorectal cancer. To address this,
we used the spontaneous colorectal cancer model, which consists of 6 alleles: Villin-Cre-
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ERT2; APCflox/flox; p53flox/flox; tetO-LSL-KrasG12D; Rosa26-LSL-Luc; Rosa26-LSL-rtTAeGFP. These mice were bred with αSMA-TK and αSMA-RFP transgenic mice for
selective targeting and monitoring of myofibroblasts in the tumor microenvironment in
these eight allelic transgenic mice.
Mice with αSMA+ myofibroblast-depleted tumors exhibited hind limb paresis, which
likely contributed to their decreased overall survival. Intraluminal tumor burden appeared
reduced in myofibroblast-depleted tumors; however, the tumors were depressed resulting
in more invasion to both the vascular and lymphatic vessels. The depletion of
myofibroblast surprising resulted in increased deposition of ECM and generation of an
immunosuppressive microenvironment with the accumulation of CD4+ Foxp3+ Treg.
Furthermore, we discovered that the population of cancer stem cells expressing Lgr5 and
Dclk1 was increased in αSMA+ myofibroblast-depleted tumors. In conclusion, our study
reveals the unknown functional role of myofibroblasts in regulating T cell-meditated antitumor immunity and stemness features in colon cancer cells.
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Chapter 1: Introduction
Epidemiology of colorectal cancers
Colorectal cancers (CRCs) are a frequently lethal disease with heterogeneous outcomes
and drug responses. Incidence is low at ages younger than 50 years but strongly increases
with ages. Median age at diagnosis is around 70 years in developed countries [1]. The
highest incidence has been reported in countries of Europe, North America, whereas
incidence is lowest in some countries of south and central Asia and Africa [2]. In the
United States, CRC is the second or third leading cause of cancer and cancer-related
deaths, with a 2016 estimate 134,490 new cases diagnosed and 49,190 death. The lifetime
risk of developing CRC is as high as 5% in the American population.
The prognosis of patients with CRC has slowly but steadily improved during past
decades in many Western countries. Overall survival decreases with age and relative
survival at the young age is slightly higher for women than for men. The Stage at
diagnosis is the most critical prognostic factor. In the United States in 2001 - 2007, 5year survival rate for CRC patients with a local stage was 90.1%, 69.2% for patients with
regional spread, and 11.7% for patients with distant spread [1].
Epidemiological studies have identified that no single risk factor accounts for most cases
of CRC. The following risk factors such as family history of CRC [3], inflammatory
bowel disease [4], smoking [5], excessive alcohol consumption [6], high consumption of
red and processed meat [7], obesity [8], and diabetes [9] co-occur and interact for
development of CRC. Further recent evidence suggested that infection of Helicobacter
pylori and Fusobacterium spp. could be associated with an increased risk of CRC
incidence [10, 11]. Established preventive factors contain physical activity [12],
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treatment of hormone replacement therapy [13] and aspirin [14, 15], and removal of
precancerous lesions via endoscopic procedure showing most promising risk reduction
[16, 17].

Histopathological classification of colorectal cancers
CRCs are histopathologically classified according to local invasion depth (T stage),
lymph node dissemination (N stage), and the presence of distal metastasis (M stage)
(Table 1) [131]. These classifications are combined into overall stage definition to
provide the decision for therapeutic treatments (Table 2). Although this classification
according to TNM stage provides valuable prognostic information and guide therapeutic
decisions, the outcome of CRC patients’ treatment is difficult to predict.

Diagnosis and staging of colorectal cancers
A general diagnosis of CRCs depends on biopsy samples taken during endoscopy.
Complete endoscopy or computed tomography (CT) endoscopy is necessary to detect
synchronous cancers that are present in about 2 - 4 % of CRC patients [18]. For rectal
cancer, exact local staging at the time of diagnosis is critical for neoadjuvant treatment.
Endoscopic ultrasonography is the accurate method for determination of regional T stage
of rectal cancer because of its accuracy to determine between non-invasive and invasive
phenotype [19]. Magnetic Resonance Imaging (MRI) is the most accurate method to
define advanced T stage of rectal cancer [20].
The most common location of metastasis in CRC patients is the liver, and a meta-analysis
with patients without any treatments display that the sensitivity of MRI is slightly higher
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than that of CT [21] Especially, MRI had significantly higher sensitivity than CT for
small tumors less than 10 mm. Abdominal ultrasonography is the common diagnostic
method for detection of many cancers in the abdomen, but its sensitivity to detect liver
metastasis was lower than any other staging methods [22]. To identify lung metastasis,
the chest radiograph is utilized, and chest CT considers as another option for patients
with locally advanced rectal cancers [23].

Standard cares of colorectal cancers
The surgery is the main treatment for early-stage CRCs. The standard surgical procedure
for early treatment of rectal caner patients is excision of total mesorectum [24]. Complete
removal of the mesorectum is critical because it contains most of the tumor deposits and
involved lymph nodes [25]. For colon cancer patients, the tumors and the surrounding
lymphatic vessels are surgically removed. Unlike open surgery, laparoscopic resection
provides the patients with reduced blood transfusions, faster return of bowel function, and
a shorter duration of hospital stay. However, operating times are longer, and operative
costs are higher than open surgery.
The role of neoadjuvant therapies including radiotherapy and chemotherapy is not only to
downsizing or staging of tumors but also to reduce local recurrence rates after surgery.
Patients with stage I CRCs are not necessary for any treatments before surgery because
local recurrence rate is less than 3% [26]. These clinical treatments are known to provide
benefits for patients with T4 and advanced T3 tumors infiltrating mesorectal fascia.
Patients with stage III CRCs have a high risk of recurrence rating between 15% and 50%.
Adjuvant chemotherapy, therefore, is highly recommended for all patients with stage III
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CRCs after curative resection. Fluorouracil treatment reduced the recurrence rate by 17%
and increased five-year disease free survival (DFS) by 13-15% [27]. Alternatively,
Capecitabine, an oral prodrug of fluorouracil has been used for comparable efficacy [28].
Additionally, oxaliplatin increased the 5-year disease-free survival rate by 6.2% to 7.5%
and overall survival by 2.7% to 4.2% in patients with stage III CRCs [29, 30].

Molecular pathogenesis of colorectal cancers
The patterns of the molecular pathogenesis of CRCs are highly heterogeneous. The
molecular mechanisms underlying development and progression of CRCs are clinically
important because they are tightly associated with the prognosis and therapeutic
approaches of patients [31, 32]. During past two decades, therefore, the identification of
molecular mechanisms including genetic alterations has been focused on improving
responses to treatments.
One of the most critical fundamental concepts of colorectal tumorigenesis is adenomacarcinoma sequence, a term that describes the stepwise progression from normal
epithelium to dysplastic lesion called adenoma to carcinoma associated with the
accumulation of multiple genetic alterations [33]. The concept was first proposed by
Fearon and Vogelstein in 1990 and postulated that mutational activation of oncogenes,
coupled with mutational inactivation of tumor suppressor genes leads to the development
of colorectal cancer. They tested their hypothesis by measuring the frequency of ras gene
mutation and loss of p53 in early adenoma, intermediated adenoma, late adenoma, and
carcinoma. Approximately 50% of colorectal carcinomas and the similar percentage of
intermediated adenoma and late adenoma have been found ras mutation. However only
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10% of early adenomas have exhibited ras mutation. The loss of a large portion of p53
has been seen in more than 75% of carcinoma, but such loss is infrequent in any stages of
adenomas [34].
CRCs often develop over more than 10 years and dysplastic adenomas are the most
common form of premalignant precursor lesions [35]. One of the mutations known to
occur early in the adenoma-carcinoma progression is the adenomatous polyposis coli
(APC) tumor suppressor gene located on chromosome 5q21 in human [132] [36] and,
this mutation occurs in more than 70% of adenomas [37]. The protein of APC gene is a
large 312-kDa protein composed 2843 amino acids. It is known as a multifunctional
protein with several domains that interact with several proteins including the β-catenin,
glycogen synthase kinase (GSK) 3β, and end binding protein (EB) 1 [38-40]. One critical
function of APC to colorectal tumorigenesis is the regulation of intracellular β-catenin
levels. Wild-type APC protein forms a complex with β-catenin and GSK-3β, which leads
to an enhanced rate of β-catenin degradation by the ubiquitin-proteasome pathway. Cterminally truncated mutant APC proteins, however, lack of β-catenin binding site, cause
to increase intracellular β-catenin level [133] [41]. The importance of β-catenin relates to
its capacity to bind T-cell factor (TCF) family of transcriptional factors and activate gene
transcriptions [42]. Increased β-catenin-TCF-meditated transcription has been
demonstrated in tumors with APC mutations and β-catenin mutation and results in
increased transcriptional activity of target genes such as oncogenic c-myc [134].
An additional genetic alteration presumably occurs early in the adenoma-carcinoma
progression is the mutation in the K-ras gene. K-ras is one of three members of Ras
family located on the short arm of chromosome 12 and associated with somatic mutations
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in many human cancers. The type of K-ras somatic mutations found in around 40% of
CRCs is point mutations affecting codon 12, 13, or 61. Especially, more than 75% of the
K-ras point mutations occur at the codon 12. Only small fraction (< 5%) of CRCs has Nras mutations at codon 12, 13, or 61 [34]. K-ras encodes 21-kDa protein critically
involved in signal transduction of regulatory pathways for proliferation and
differentiation [43]. It is guanosine 5'-triphosphate (GTP)-binding protein, located at the
cytoplasmic aspect of the cell membrane. When bound to GTP, the ras protein is active
but becomes inactive when GTP is hydrolysed to guanosine 5’-diphosphate. Mutations of
the K-ras oncogene impact the GTP-binding domain, decrease its GTPase activity and
result in a constitutively active Ras protein [137].
The p53 gene is the most frequently mutated in human cancers, which located on short
arm of chromosome 17 [44]. The functional role of p53 is to block cell proliferation in
the presence of DNA damage, to stimulate DNA repair, and promote apoptotic cell death
if repair is not sufficient [45]. Loss of p53 function, therefore, results in propagation of
damaged DNA to daughter cells. Functional inactivation of p53 most often occurs as a
result of missense mutations in the DNA-binding domain, but it can result from
oncogenic viral or cellular protein interaction [46, 47]. The alteration of p53 has been
reported in 4-26 percent of adenomas, in approximately 50 percent of invasive foci within
adenomatous polyps, and in 50-75 percent of adenocarcinomas [48], [135-136]. These
results lead to the belief that functional inactivation of p53 protein is associated with the
transition from adenoma to carcinoma.
However, more than 15% of sporadic CRCs develop through fundamentally different
molecular events instead of generic adenoma-carcinoma sequence. These subtypes of
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tumors are originated from serrated precursor lesions and often characterized by the CpG
island methylation and activating oncogenic BRAF mutations. It is difficult to identify
these lesions during colonoscopy because these cancers are relatively flat and
inconspicuous characteristics [49]. Most cancers arising from serrated adenomas show
the high-level microsatellite instability (MSI-H) phenotype as a result of promoter
methylation of MLH1 gene [50], and appear in the proximal colon of elderly women [51].
Hereditary CRCs contribute to around 3-5% of all CRC cases [52, 53]. Dissecting
mechanisms related to hereditary forms is valuable to study molecular pathogenesis of
CRCs. Hereditary CRCs display inactivated tumor suppressor genes or DNA repair genes
by a germ line mutation and a somatic event abrogating the remaining wild-type allele
leading to tumor formation [54]. The two most common forms of hereditary CRCs are
hereditary non-polyposis colon cancer (Lynch syndrome) and familial adenomatous
polyposis coli (FAP). Both syndromes are autosomal dominant disorders. Whereas Lynch
syndrome indicates mismatch repair deficiency and MSI-H [52, 55], FAP syndrome
follows the classic adenoma-carcinoma sequence [56].
Mismatch repair deficient CRCs are defined by the accumulation of insertion and
deletion mutations at microsatellites spread along the genome [55]. Clinical
characteristics of MSI-H cancers exhibit development of tumors in the proximal colon,
the symptom in people younger than 50 years (hereditary form) or elderly people
(sporadic form), simultaneous occurrence of additional cancers [57], and relatively large
primary tumors with rare distal metastasis. Histopathologically, MSI-H cancers display
poor or mixed differentiation with dense infiltration with tumor infiltrating lymphocytes
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and expansive pattern of invasion [58]. MSI-H cancers also exhibit loss of expression of
at least one DNA mismatch repair protein in greater than 90% of lesions [59].

Tumor microenvironment (TME)
In CRCs, the multistep process from normal colonic epithelium to an adenomatous polyp
and ultimately to an invasive adenocarcinoma is associated with a robust desmoplastic
reaction, which generates complex tumor microenvironment. Desmoplasia is activation
of stoma cells by cancer cells not only to eliminate the pre-existing extracellular matrix
but also to induce new matrix formation [60]. The tumor microenvironment consists of
cells of hematopoietic origin, cells of mesenchymal origin, active angiogenesis,
extracellular matrix (ECM), and proteins and remodeling enzymes [61, 62].
Local inflammation at the site of solid tumors causes the accumulation of a variety of
cells, and it is now widely accepted that these cells are intimately linked to the control of
tumor growth. CRC, similarly to many other solid tumors, are infiltrated by immune cells
such as tumor-associated macrophages (TAMs), myeloid-derived suppressor cells
(MDSCs), monocytes, neutrophils, T cells, B cells, NK cells, and dendritic cells (DCs)
and stroma cells such as endothelial cells, endothelial progenitor cells (EPCs), pericytes,
platelets, mesenchymal stem cells (MSCs), and cancer-associated fibroblasts (CAFs).
TAMs are typically derived from blood monocytes that are recruited to the tumors by
growth factors and chemokines such as vascular endothelial growth factor (VEGF),
colony-stimulating factor-1 (CSF-1), CCL2, CCL3, CCL4, CCL5, and angiopoietin-2
[63]. Recruited monocytes differentiate into TAM upon the presence of low interleukin
(IL)-12 and high IL-10 concentration in TME [64]. It has been well established that
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macrophage-deriving tumor necrosis factor (TNF) – α, IL-1β, and IL-6 induce human
colon cancer cell proliferation and migration, and also colon cancer cells stimulate
macrophages to produce IL-6 via signal transducer and activator of transcription 3
(STAT3) – mediated IL-10 production [65, 66]. (explaining in detail) Clinically, elevated
IL-10 and IL-6 are associated with a poor prognosis in CRC patients [67].
MDSCs are immature myeloid cells that have the immunosuppressive affect. The
suppressive effects of MDSCs are associated with metabolism of L-arginine that is the
substrate for arginase-1 and inducible nitric oxide synthase (iNOS). Arginase-1 degrades
arginine in TME, which affect translational blockade of ε chain of CD3 leading to
prevention of T cell stimulation from tumor antigens. iNOS-mediated nitric oxide (NO)
production inhibits T cell function via a variety of different mechanisms including the
blockade of phosphorylation and activation of Janus kinase 3 and STAT5, inhibition of
MHC-II gene expression, and induction of T cell apoptosis [68]. Also, there is emerging
evidence that MDSCs promote the development of Foxp3+ Tregs by releasing IL-10 and
TGF-β [69]. It is widely known that the number of MDSCs is increased in the blood of
patients with solid cancers including CRCs [70].
CD4+ CD25+ Foxp3+ Tregs are also expanded in TME and are capable of suppressing the
proliferation of cytotoxic and effector T cells through direct contact or IL-10 and TGF-β
production. IL-17-producing CD4+ CD25+ Foxp3+ Tregs expanded in colonic polyps
promotes mastocytosis and tumor-promoting inflammation [71]. Also, CD4+ CD25+
Foxp3+ Tregs express cyclooxygenase-2 (COX-2) which are overexpressed in the
majority of CRCs [72] and COX-2-derived prostaglandin E2 (PGE2) promote tumor
growth by inducing cell proliferation, survival, and invasion [73]. Treatment of long-term
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nonsteroidal anti-inflammatory drugs (NSAIDs) increased the levels of MHC II proteins
such as HLA-DP, HLA-DQ, and HLA-DR, and infiltration of CD4+ effector T cells and
CD8+ cytotoxic T cells in TME along with decreased Treg-associated molecules
including IL-10 and Foxp3 [74, 75].

Fibroblasts
Fibroblasts are dominant population of tumor stroma, and many studies suggested that
these cells support cancer progression and metastasis [76, 77]. Fibroblasts in TME have
been termed cancer-associated fibroblasts (CAFs), tumor-associated fibroblasts (TAFs),
activated fibroblasts or myofibroblasts. CAFs are considered as a major contributor of
fibrotic stroma in many solid tumors [78, 79].
Fibroblasts are non-epithelial cells and non-immune cells with the mesenchymal origin
and a part of connective tissues [138]. Fibroblasts in healthy tissue are quiescent with
negligible metabolic activity. The fibroblasts are usually resting state and become
activated in a wound healing response [80]. These activated fibroblasts were termed as
myofibroblasts. Myofibroblasts are regarded as involving acute and chronic inflammation
and tissue fibrosis [81, 82].
Fibroblasts in mammals are highly heterogeneous, and fibroblasts isolated from different
organs reflect tremendous topographic diversity. A recent study by using the genomewide expression patterns of human fibroblast culture isolated from 16 various sites
indicated that the gene expression pattern of human fibroblast lineage is comparable with
that of human white blood cells [83]. There are several well-established fibroblast
markers including vimentin, alpha-smooth muscle actin (αSMA), Desmin, Fibroblast-

10

specific protein1 (FSP-1), and Fibroblast-activation protein (FAP), but none of them are
commonly expressed fibroblast lineage [84].
Myofibroblasts are spindle shape of contractile cells functioning as remodeling of
damaged tissues. The transition from fibroblast to myofibroblasts during wound healing
is a stepwise process in which fibroblast first differentiate into proto myofibroblasts by
expressing β-cytoplasmic actin and γ-cytoplasmic actin and then fully differentiate into
myofibroblasts which express αSMA [85].
αSMA is currently considered the most common marker of intestinal myofibroblasts that
also expressed on pericytes, bone marrow-derived mesenchymal stromal cells, muscularis
mucosae smooth muscle cells, and mural cell associated with lymphatic lacteals. αSMA
expressing cells in the core of villi are mostly pericytes where αSMA expressing cells
located in under epithelial layer around crypts of small and large intestines are
myofibroblasts [86].
Fibroblasts play a critical role in all stages of cancer progression including tumor
initiation, growth, invasion, and metastasis. Mostly this involvement of fibroblasts in
cancer is typically based on their specific functions in each stage of cancer. In the 1970s,
several studies led to the consideration that cancer cells may recruit activated fibroblasts
[139] [87, 88]. This recruitment of fibroblasts is regulated by the growth factors released
by cancer cells and other immune cells. The recruitment of activated fibroblasts is mainly
associated with transforming growth factor-β (TGF- β) and also the proliferation of CAFs
is regulated by TGF- β [89, 90]. The role of CAFs in TME may involve the crosstalk with
cancer cell to promote tumor growth and stemness, immunosurveillance, activation of
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angiogenesis, tumor-promoting inflammation, and ECM remodeling that facilitate
metastasis.

Cancer stem cells
The intestine is one of most rapidly renewing tissues in the human body in that the entire
epithelial layer is replaced within every 5 days. This rapid process is maintained by
intestinal stem cells (ISCs) that localize in the bottom of the crypt and generate precursor
cells. These precursor cells differentiate into specialized cells, mainly enterocytes that
uptake nutrients as well as transport and remove faeces that is facilitated by mucinproducing goblet cells [91]. Another abundant differentiated cells are hormone-producing
enteroendocrine cells and Paneth cells. Paneth cells reside at the bottom of crypt, function
in intestinal immunity, and contribute to the formation of the ISCs niche [92].
Due to its high turnover rate, the intestinal epithelium is subject to malignant
transformation like CRCs. Interestingly, the biology of ISCs and CRCs is highly
interconnected. Signaling pathways that regulate ISC function such as WNT signaling are
aberrantly activated in CRC patients [34]. Most of the intestinal cancers originate from
initial transforming events in the ISC compartment. Cancer cells that share properties of
ISCs, including multilineage potential and self-renewal, appeared in CRCs and are
referred to colon cancer stem cells (CSCs) [93]. These CSCs are thought to contribute to
tumor growth and progression, but there are still many unknown properties regarding
their identification and importance for clinical implication.
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Definition
T stage
Tx

No information about local tumour infiltration available

Tis

Tumour restricted to mucosa, no infiltration of lamina muscularis mucosae

T1

Infiltration through lamina muscularis mucosae into submucosa,
no infiltration of lamina muscularis propria

T2

Infiltration into, but not beyond, lamina muscularis propria

T3

Infiltration into subserosa or non-peritonealised pericolic or perirectal tissue,
or both; no infiltration of serosa or neighboring organs

T4a

Infiltration of the serosa

T4b

Infiltration of neighboring tissues or organs

N stage
Nx

No information about lymph node involvement available

N0

No lymph node involvement

N1a

Cancer cells detectable in 1 regional lymph node

N1b

Cancer cells detectable in 2–3 regional lymph nodes

N2a

Tumour satellites in subserosa or pericolicor perirectal fat tissue,
regional lymph nodes not involved

N2b

Cancer cells detectable in 4–6 regional lymph nodes

N2b

Cancer cells detectable in 7 or greater regional lymph nodes

M Stage
Mx

No information about distant metastases available

M0

No distant metastases detectable

M1a

Metastasis to 1 distant organ or distant lymph nodes

M1b

Metastasis to more than 1 distant organ or set of distant lymph nodes
or peritoneal metastasis

Table 1. Classification of CRC according to local invasion depth (T stage), lymph node
involvement (N stage), and presence of distant metastases (M stage)
Adapted by Fl. Obrocea et al, (2011) [131]
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T stage

N stage

M stage

Stage 0

Tis

N0

M0

Stage I

T1/T2

N0

M0

Stage II

T3/T4

N0

M0

IIA

T3

N0

M0

IIB

T4a

N0

M0

IIC

T4b

N0

M0

Stage III

Any

N+

M0

IIIA

T1-T2

N1

M0

T1

N2a

M0

T3-T4a

N1

M0

T2-T3

N2a

M0

T1-T2

N2b

M0

T4a

N2a

M0

T3-T4a

N2b

M0

T4b

N1-N2

M0

Stage IV

Any

Any

M+

IVA

Any

Any

M1a

IVB

Any

Any

M1b

IIIB

IIIC

Table 2. Overall stage classification of CRCs
Adapted by Fl. Obrocea et al, (2011) [131]
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Chapter 2: Material and methods
Mice
Mouse colorectal cancer model containing six genetic alleles; VillinCreERT2; tetO-LoxStop-Lox-KrasG12D; ROSA26-Lox-Stop-Lox-rtTA-IRES-EGFP; APCfl/fl; P53fl/fl; ROSA26Lox-Stop-Lox-Luciferase (herein referred to as iKrAP) mice were kindly provided by Dr.
Adam T. Boutin in the laboratory of Dr. Ronald A. DePinho at MD Anderson Cancer
Center (MDACC). Tamoxifen-dependent Cre recombinase (VillinCreERT2) was expressed
under the control of a 9 kb regulatory region of villin gene and led to spatiotemporally
controlled somatic recombination for targeted genes after tamoxifen administration. tetOLox-Stop-Lox-KrasG12D transgene was controlled by tetracycline-response operon
promoter element (tetO) with a lox-stop-lox cassette inserted between the promoter and
the start codon of the KrasG12D open reading frame. The Cre recombinase-mediated
excision of a STOP codon in ROSA26-Lox-Stop-Lox-rtTA-IRES-EGFP transgeneinduced functional reverse tetracycline transactivator (rtTA) and EGFP activity, which
were inserted between exon 1 and exon 2 in the ROSA26 locus. In the presence of
doxycycline, rtTA bound to tetO and initiated transcription of KrasG12D. Conditional APC
knockout was regulated by Cre-loxP strategy leading to deletion of exon 14 and
generation of a frameshift mutation at AA580 that disrupted that APC gene.
iKrAP mice were first bred with αSMA-TK mice and then bred with αSMA-RFP mice.
All mice were housed under standard housing conditions at MDACC animal facilities,
and all animal procedures were reviewed and approved by the MDACC Institutional
Animal Care and Use Committee.
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Tumor induction
4-OH tamoxifen (Sigma-Aldrich, H7904) was solubilized in 100% ethanol (50 mg/ml)
and diluted to 1 mg/ml in 100% ethanol. iKrAP; αSMA-TK; αSMA-RFP mouse (8-10
weeks of ages) of known weight was lightly anesthetized by placing in a plastic chamber
containing isoflurane. A 20 gauge and 30 mm plastic feeding tube (Instech, FTP203050)
attached to 1 ml disposal syringe was filled with 1mg/ml of 4-OH tamoxifen mixture, and
the tube was lubricated by dipping the soft elastomer tip in surgical lubricant. The
anesthetized mouse was held by the tail. A plastic feeding tube was inserted into the anus
around 2 to 2.5 cm and 50 ul of 1 mg/ml of 4-OH tamoxifen mixture was injected into its
rectum. The mouse was held by the tail in a vertical position, head down, for 30 sec to
allow uniform distribution of the 4-OH tamoxifen mixture before putting the mouse back
in its cage. The moue was fed with Doxycycline pellets (200 mg/kg, BioServ, S3888)
instead of normal chow after intrarectal administration of 4-OH tamoxifen mixture.

Endoscopic procedures
For monitoring the tumorigenesis, Storz Veterinary video endoscopic system was utilized
(Karl Storz, Germany). The endoscopic system consisted of a miniature endoscope
(scope 1.9 mm outer membrane) including a telescope and a telescope sheath, a light
source, a camera console, USB recorder, a monitor, and an endoflator to regulate inflated
mouse colon. The endoscopic procedure was viewed on a color monitor and digitally
recorded on USB flash drive. Before anesthetizing the mouse, an endoscope and a camera
console were assembled and were sterilized by dipping the tip in 10% bleach and 70%
ethanol to prevent disease transmission. The mouse was anesthetized by placing in a
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plastic chamber containing isoflurane until completely anesthetized. A 20 ga x 30 mm
plastic feeding tube attached to 10 ml disposal syringe was filled with a warm PBS. The
tube was coated with the sterile surgical lubricant and inserted into the anus to flush the
colon with a warm PBS enema (10ml). The anesthetized mouse was placed on the
operation table applied with the nose cone that provided the inhalation anesthesia to the
mouse. The lubricated endoscope was inserted into the anus and advanced through the
rectum. The air from an endoflator was slowly applied to set apart the intestinal walls.
The rectum and colon were carefully assessed and monitored, and the video was recorded
if tumors and colonic inflammation were identified. Upon the completion of examination,
the endoscope was slowly withdrawn, and the mouse was provided with a warm
environment in which its cage was placed on a warm pad. The mouse was monitored
closely until full recovery.

GCV treatment
Ganciclovir (GCV) was utilized to obtain a suicide effect in αSMA-TK+ cells. GCV is an
analog of deoxyguanosine used as a substrate, which is converted into GCV-triphosphate
(GCV-TP) by cellular thymidine kinases. GCV-TP incorporated in DNA that led to
premature termination of DNA and subsequently cell death. GCV (InvivoGen) was
reconstituted with 20 ml of sterile water, and its pH was adjusted to 12 with NaOH 1M
because GCV is only soluble at pH ≥ 12. GCV solution’s pH was lowered to 11, and 5 ml
of sterile water was added to obtain a solution at 10 mg/ml. A 0.22 um sterile filter was
used to sterilize GCV solution and its aliquots were stored at -20°C. For in vivo
treatment, the concentration of the stock solution (10 mg/ml) was diluted to 5 mg/ml by
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adding the same volume of sterile PBS. The mouse was received daily intraperitoneal
(i.p.) injections of 2.5 mg of GCV.

Survival study
For survival study, the time of the death is most critical endpoint. In this study, the
euthanizing mice with more than 5mm or actively bleeding prolapsed rectum were
considered as false results and removed from survival study. Daily GCV treatment via
i.p. injection was initiated at 37 days post tumor induction (n = 24 animals for iKrAP;
αSMA-TK- group and n = 32 animals for iKrAP; αSMA-TK+ group), and animals
continued to receive treatment until they became moribund, which was assessed on the
signs of distress and endpoints including weight loss (> 20%), hunching, prostration,
impaired motility, and ruffled haircoat. Mice exhibiting limb paresis were evaluated
again 6 hours later. Then if mice worsened, they were euthanized and considered as nonsurvivors.

Histology scoring for local invasion
The H&E slides from each sample were examined blindly by an investigator and were
evaluated in the light microscope. The invasion scoring is based upon the measurement of
the deepest point of primary tumors. The measurement of invasion depth was categorized
into four scales: 0 (no invasion), 1 (invasion of muscularis mucosa), 2 (invasion of
submucosa), 3 (invasion of muscularis propria), and 4 (invasion of serosa).
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Immunohistochemistry
Harvested tumors and lungs were fixed in 10% neutral buffered formalin, dehydrated,
and embedded in paraffin. For αSMA immunohistochemistry, the deparaffinized tumor
sections were incubated in 10mM citrate buffer (pH 6.0) for 1 hour at boiling temperature
before blocking with M.O.M. Mouse IgG Blocking Reagent (Vector Laboratories, West
Grove, PA) for 1 hour. Sections were incubated with αSMA antibody (1:200, Daco.)
overnight at 4°C, followed by incubation with biotin-conjugated anti-rabbit/rat/mouse
IgG and ABC reagent (Vector Laboratories, West Grove, PA) for 30 min each at room
temperature. The sections were then developed by DAB staining according to the
manufacturer’s instructions. For collagen 1(1:200, MP bioscience), β-catenin (1:200,
Abcam), LYVE-1 (1:200, Abcam), we used 4% of fish gel for blocking and followed
same procedures described above. In the cause of picrosirius red staining, we followed
manufacturer’s protocol (sigma-Aldrich).
For Dclk1 and CD20 staining, immunostainings were performed on frozen sections.
Frozen sections were fixed in acetone for 10 minutes at 4°C and blocked one hour with
5% donkey or goat serum in PBST at room temperature. Following blocking, sections
were incubated in 1:200 rat anti- Dclk1 (Abcam) and CK20 (Abcam) at 4°C overnight,
followed by fluorescent secondary antibodies. Slides were mounted after DAPI staining,
labeling nuclei blue.

Flowcytometry
Tumors were excised and cut into 1-2mm2 pieces. Digestion was performed by
incubating the small pieces at 37°C for one hour in RPMI 1640 medium supplemented
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with 0.15µg/ml of DNase I(Invitrogen), 40U of Dispase I(Sigma), and 100U/ml of
collagenase VIII (Sigma). Following initial one-hour incubation, the pieces were
vortexed intensively and then incubated at 37°C for 5 min, repeating this step until
complete digestion. The digestion solution was passed through a 100µm cell strainer and
washed with RPMI 1640 medium. The cells were resuspended with anti-mouse CD16/32
and then staining with anti-CD4, CD8, F4/80, CD3e, Gr1, Ly-6C, CD11b, CD19, NK1.1,
and CD45 conjugated with fluorochromes.
For Foxp3 staining, Cells were incubated at 37°C for 3 hours with 50ng/ml of PMA
(Sigma), 500ng/ml of Ionomycin (Sigma) to stimulate cytokine production, and
Monensin to block protein transport from endoplasmic reticulum to golgi apparatus.
Fixation and permeabilization working solution (eBioscience) were added and cells were
incubated at 4°C for 30 min in the dark. Following the incubation, the cells were stained
with conjugated anti-mouse Foxp3 antibody and fluorescently conjugated antibodies at
4°C for 15 min in the dark and resuspended in appropriate volume for flow cytometric
analysis using LSR II.

Circulating tumor cell (CTC) measurement
The blood (100ul) was collected retro-orbitally from iKrAP; αSMA-RFP; αSMA-TK- and
iKrAP; αSMA-RFP; αSMA-TK+ mice and incubated twice with 1ml of ACK lysing
buffer (A1049201, ThermoFish Scientific) at room temperature to lyse red blood cells.
ACK-treated cells were washed twice with cold PBS and resuspended in 2% FBS
containing PBS. The number of GFP+ cells was analyzed by flow cytometry (BD
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LSRFortessa X-20 Cell Analyzer, BD Biosciences). The data was indicated by the
percentage of GFP+ cells among 1 × 105 cells.

RNA-Seq
Tumors were harvested from iKrAP; αSMA-RFP; αSMA-TK- and iKrAP; αSMA-RFP;
αSMA-TK+ mice. 1ml of TRIzol Reagent (Life Technologies) was added into 50 –
100mg of samples. Tissues were homogenized by a tissue homogenizer, and
homogenized sample were incubated for 5 minutes at room temperature. 200ul of
chloroform per 1ml of TRIzol Reagent were added, and the mixtures were vigorously
shaken by hand for 15 seconds. The mixtures were centrifuged at 12,000 x g for 15
minutes at 4 °C. The aqueous phase of the mixtures was collected by pipetting. 0.5ml of
100% isopropanol was added into the aqueous phase per 1ml of TRIzol Reagent, and
incubate at room temperature for 10 minutes. The samples were centrifuged at 12,000 x g
for 10 minutes at 4 °C. To wash pellets, 1ml of 75% ethanol per 1ml of TRIzol Reagent
was used, and vortex the samples briefly. The samples were centrifuged at 7,500 x g for 5
minutes at 4 °C. We did air dry RNA pellet for 10 minutes, and added DEPC water.
The RNA-seq was carried out with three biological replicates. Illumina HiSeq 2000 was
utilized with 76nt PE sequencing format. A threshold of q value < 0.05 was used. Gene
set enrichment analyses (GESA) were performed with GSEA platform of the Broad
Institute.
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Chapter 3: αSMA+ myofibroblast-ablated tumors exhibit poor survival in
murine CRC model.
CRC irresponsive to therapy is a lethal disease. Therefore, innovative treatments that
eradicate primary tumors and prevent metastatic dissemination to distal organs are
necessary to improve our capability to cure CRC patients. Tumor microenvironment
(TME) had long been regarded as a key cellular regulator of the multi-step tumorigenesis
in CRC. The TME in CRC is quite distinct from the standard tissue microenvironment,
and it is composed of intra-tumoral bacteria and a particular phenotype of immune cells
and stromal cells including tumor-associated macrophages (TAMs), tumor-associated
neutrophils (TANs), and cancer-associated fibroblasts (CAFs). CAFs have been mainly
known as a potential therapeutic target to tumor progression and metastasis in CRC due
to their pro-angiogenic and immunosuppressive characteristics in vitro settings. A Recent
study has revealed that depletion of CAFs constitutes a protective response from the host
rather than the pro-tumorigenic role in pancreatic ductal adenocarcinoma [94]. Another
study demonstrated that fibroblast-restricted deletion of IKKβ upregulated intestinal
epithelial proliferation of intestinal epithelial cells, suppressed apoptosis of cancer cells,
and promoted the recruitment of CD4+Foxp3+ Tregs [95].
Based on the previous finding, CAFs have a much wider range of functions. It is not clear
that functions of different subtypes and signaling pathway involved between CAFs and
other cells in tumor microenvironment.
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Mouse model for spontaneous colorectal cancer
In this study, we utilized a spontaneous mouse model for colorectal cancer (iKrAP)
containing six alleles: Villin-Cre-ERT2; APCflox/flox; p53flox/flox; tetO-LSL-KrasG12D;
Rosa26-LSL-Luc; Rosa26-LSL-rtTA-GFP provided by Dr. Adam Boutin in Ronald
DePinho lab (Figure 1). Unlike other murine CRC models, iKrAP mice reliably
recapitulate the genetic and histopathological features of human diseases including
adenoma-carcinoma progression, abundant stroma, and distal metastasis.
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Figure 1. Spontaneous mouse colorectal cancer mice. Mouse colorectal cancer model
containing six genetic alleles; Villin
fl/fl

CreERT2

; tetO-Lox-Stop-Lox-Kras

G12D

; ROSA26-Lox-Stop-Lox-

fl/fl

rtTA-IRES-EGFP; APC ; P53 ; ROSA26-Lox-Stop-Lox-Luciferase. Tamoxifen-dependent Cre
recombinase excision of STOP codon induce deletion of exon 14 in APC gene, deletion of exon
2-10 in p53 gene, and activation of rtTA. In the presence of doxycycline, rtTA binds tetO and
initiate transcription of Kras

G12D

.

αSMA+ myofibroblasts depletion is associated with decreased survival
To understand the functional significance of αSMA+ myofibroblasts in disease
progression of colorectal cancer, we crossed iKrAP mice with αSMA-TK and αSMARFP mice that express viral thymidine kinase under control of αSMA promoter (Figure
2). Viral thymidine kinase phosphorylates Ganciclovir (GCV) to GCV-monophosphate,
which is further converted to GCV-diphosphate and GCV-triphosphate by host kinases.
Therefore, the treatment of GCV in αSMA-TK+ mice results in the selective elimination
of proliferating αSMA+ cells due to incorporation of GCV-triphosphate in DNA as an
analog of deoxyguanosine by polymerase during replication, leading to termination of
DNA synthesis and subsequently cell death while αSMA+ cells in αSMA-TK- mice have
no effect with GCV treatment [96, 97] (Figure 3).
Tumors were introduced at 8 to10 weeks ages of iKrAP; αSMA-TK- and iKrAP; αSMATK+ mice by intrarectal injection of 4-hydoxy tamoxifen and doxycycline diet. Villin has
expressed microvilli of the brush border of epithelium in both small and large intestine23.
Injection of tamoxifen though IP route causes severe damages to both small and large
intestinal epithelium and all of the mice were moribund within two weeks (Data not
shown). Therefore, we introduce tamoxifen only via intrarectal anemia. One month later,
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endoscopy was performed for tumor incidence. Seven days post endoscopy, we daily
treated GCV via intraperitoneal injection (IP) (Figure 4).
αSMA+ myofibroblast depletion is associated with significant reduction of survival
(Figure 5). Around 60% of iKrAP; αSMA-TK+ mice developed hind limb paresis
whereas all of the iKrAP; αSMA-TK- mice were moribund because of bowel obstruction
(Figure 6).
Immunohistochemical analysis of αSMA revealed around 70% reduction of αSMA+
myofibroblasts in αSMA-TK+ mice (Figure 7).

Figure 2. Spontaneous mouse colorectal cancer mice were crossed with αSMA-TK and
RFP mice to targeting and monitoring, respectively. Mouse colorectal cancer model
containing six genetic alleles; Villin
fl/fl

CreERT2

; tetO-Lox-Stop-Lox-Kras

fl/fl

G12D

; ROSA26-Lox-Stop-Lox-

rtTA-IRES-EGFP; APC ; P53 ; ROSA26-Lox-Stop-Lox-Luciferase. These mice were bred with
αSMA-TK and αSMA-RFP mice.
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Figure 3. Mouse model targeting proliferating αSMA myofibroblast by treating GCV. GCV
is an analog of deoxyguanosine used as a substrate, which is converted into GCV-triphosphate
(GCV-TP) by cellular thymidine kinases. GCV-TP incorporated in DNA that led to premature
termination of DNA and subsequently cell death.
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Tumor
induction

Endoscopy
(Tumor validation)

Tissue
collection

iKrAP; αSMA-TK(Control)

Days

60 Days

iKrAP; αSMA-TK+
(Depleted)

90 Days

97 Days

Moribund

Doxycycline (1.5g/kg, diet)
4-OH Tamoxifen
(I.R. 50mg/kg once)

GCV treatment (I.P. 50mg/kg daily)

Weight
Measurement

10% of animals used for experiments

Figure 4. Experimental timeline for induction of tumors and ablation of αSMA+
myofibroblasts. Mice were intrarectally treated with 4-OH tamoxifen (50 mg/kg) and were fed
with doxycycline pellets (200 mg/kg) at 60 days of age for induction of tumors. 30 days post tumor
induction, endoscopy was performed to validate tumors in rectal and colon. At 97 days of age,
GCV were intravenously administrated in tumor-bearing mice. The mice continued to receive
GCV treatment until they became moribund.
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Figure 5. Decreased αSMA myofibroblasts correlated with poor survival. Daily GCV
treatment via i.p. injection was initiated at 37 days post tumor induction. The mice were assessed
on the sign of distress and endpoints everyday. The median survival of iKrAP; αSMA-TK+ was 28
days after treatment of GCV whereas that of iKrAP; αSMA-TK- was 41 days. (n=32; iKrAP;
αSMA-TK+, n=24; iKrAP; αSMA-, ****p<0.001, Mentel-Cox test)
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Figure 6. Ablation of αSMA myofibroblast results in limb paresis whereas non-depleted
mice were moribund due to bowel obstruction. (A) (****p<0.0001, T-Test). (B) Comparison of
the frequency of paresis (****p<0.0001, Contingency).
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Figure 7. Decreased aSMA expression in iKrAP; αSMA-TK mice. Tumor sections from iKrAP;
αSMA-TK- and iKrAP; αSMA-TK+ were immunohistochemically stained with αSMA.
Representative microscopic images and corresponding quantification (n=4; iKrAP; αSMA-TK-,
n=5; iKrAP; αSMA-TK+, Student T-Test, ****p<0.0001)

31

Chapter 4: αSMA+ myofibroblast-depleted tumors present more invasive
and metastatic phenotype
The major cause of death of CRC is the metastasis in liver and lung. The majority of
patients with metastatic CRC remain incurable, and their median survival is around two
years. Treatment and investigation of molecular characteristics in CRC only have focused
on metastatic cancer cells. However, recent studies revealed that development and
progression of CRC linked to many other aspects consisting ECM, vasculatures, CAFs,
immune cells. Mainly, CAFs are known as having tumor-promoting characteristics by
secreting growth factors, cytokines, and chemokines necessary for promoting tumor
growth and metastasis in vitro setting.
Our previous finding demonstrated that decreased αSMA+ myofibroblasts correlated with
poor survival. Therefore, we hypothesized that αSMA+ myofibroblasts-depleted tumors
display increased metastasis to blood and lymphatic vessels, lung, and liver.

iKrAP; αSMA-TK+ mice exhibited decreased extraluminal tumor burden
Vertical tumor growth is an independent prognostic parameter for patients with CRC.
Tumor size [140]. The size was significantly associated tumor progression and cancerspecific survival in most solid tumors. To investigate comparison of tumor size between
αSMA+ myofibroblasts-depleted tumors and non-depleted tumors, we harvested tissue 30
days post GCV treatment and measure tumor size, tumor number, and colon length.
Interestingly, αSMA+ myofibroblasts-depleted tumors showed that decreased
extraluminal tumor size whereas tumor numbers was no different between two groups
(Figure 8A, B). Colon length is one of indicator for colonic inflammation [98]. αSMA+
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myofibroblasts-depleted colons were shorter than non-depleted colons, suggesting that
αSMA+ myofibroblasts-depleted colons sustained more colonic inflammation (Figure
8C).
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Figure 8. Depletion of αSMA myofibroblasts results in decreased extraluminal tumor
burden and increased inflammation. (A) (B) Representative colon images from iKrAP; αSMATK- and iKrAP; αSMA-TK+ mice (C) Comparison of tumor size and number, and colon length
(n=8; iKrAP; αSMA-TK-, n=9; iKrAP; αSMA-TK+, Student T-Test, ns; no significant difference,
*p<0.05, ****p<0.0001)

αSMA+ myofibroblast-ablated tumors displayed increased frequency of local invasion.
Next, we measured local invasion score to compare aggressiveness between αSMA+
myofibroblast-depleted tumors and non-depleted tumors. CRC arose from epithelium and
grow vertically, protruding gut lumen. However, aggressive and advanced stages of CRC
invade muscularis mucosa, submucosa, muscularis propria, and serosa. We measured this
parameter based on local invasion score (Figure 9E). Non-depleted tumors typically
exhibited well-differentiated with mostly no local invasion (Figure 9A, B, F). But αSMA+
myofibroblasts-depleted tumors displayed poorly differentiated, tumor budding, immune
cell infiltration in the submucosa, and increased frequency of local invasion (Figure 9C,
D, F). In conclusion, αSMA+ myofibroblasts-depleted tumors exhibited increased overall
intraluminal tumor burden.
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Figure 9. Depletion of αSMA myofibroblasts exhibited increased frequency of local
invasion (A) (B) (C) (D) Representative microscopic images tumors from iKrAP; αSMA-TK- and
iKrAP; αSMA-TK+ mice and (F) corresponding quantification (Student T-Test, **p<0.001), (E)
Schematic diagram of scoring system for local invasion. The invasion scoring is based upon the
measurement of the deepest point of primary tumors. The measurement of invasion depth was
categorized into four scales: 0 (no invasion), 1 (invasion of muscularis mucosa), 2 (invasion of
submucosa), 3 (invasion of muscularis propria), and 4 (invasion of serosa).
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Depletion of αSMA+ myofibroblast in tumor microenvironment affected to develop
depressed tumors
Comparison of histopathological observations from previous data between two groups
indicated that αSMA+ myofibroblasts-depleted tumors were depressed and nonpolypoid
colorectal cancer which are harder to detect by colonoscopy or computed tomography
colonography but more aggressive than generic CRC, irrespective of size [99, 100]. To
further elucidate this finding, we decided to compare tumor sizes at two-time points:
before and after GCV treatment by endoscopy. Strikingly, αSMA+ myofibroblastsdepleted tumors mostly exhibited decreased tumor size whereas non-depleted tumors
display increased tumor size.
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Figure 10. αSMA myofibroblast depletion affected morphological alteration to depressed
CRC. First endoscopy was performed to both iKrAP; αSMA-TK- (n=6) and iKrAP; αSMA-TK+
(n=11)mice before GCV treatment. Once the mice became moribund, the second endoscopy was
performed. The occupancy of tumors on the gut lumen was calculated with Photoshop.
Representative colonoscopic images and corresponding quantification

41

Depletion of αSMA+ myofibroblasts increased CTCs
The major reason of cancer-related mortality is the metastasis of primary tumors to distal
organs. During efficient dissemination, tumor cells invade the nearby tissues and organs
of primary tumors, intravasate into blood vessels, migrate distant tissues, extravasate,
adapt to new microenvironment, and eventually colonize to form metastasis [101].
The presence of CTCs in cancer patients was first described in 1869 [102] and many
studies in past decade have shown that CTCs may be used as a biomarker to predict
disease progression and survival in metastatic tumors. High CTCs numbers were
relatively correlated with aggressive disease, increased metastasis, and reduced survival.
To investigate whether depletion of αSMA+ myofibroblasts impacts metastasis, the
number of GFP+ CTCs from iKrAP; αSMA-TK- and iKrAP; αSMA-TK+ mice was
counted by FACS. We found that iKrAP; αSMA-TK+ showed dramatically increased
CTC number (Figure 11).
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Figure 11. iKrAP; αSMA-TK showed increased CTC number. The blood was collected from
iKrAP; αSMA-TK- and iKrAP; αSMA-TK+ mice after GCV treatment. GFP+ cells were counted by
FACS. Representative FACS images and corresponding quantification (Student T-Test, **p<0.01)
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Depletion of αSMA+ myofibroblasts increased metastasis to lymphatic system
Lymph node metastasis is the key factor for prognosis of CRC. The 5-year survival of
patients with lymph node-negative disease is around 70-80% in contrast to 30-60% in
those with lymph node-positive disease [103].
To study whether depletion of αSMA+ myofibroblasts impacts metastasis of cancer cells
to lymph nodes, we first utilized immunohistochemical analysis for lymphovascular
invasion with lyve-1. αSMA+ myofibroblast depleted tumors exhibited significantly
increased invasion of cancer cells to lymphatic vessels (Figure 12).
Next, we further investigated that increased lymphatic vessel invasion correlated with
local lymph node metastasis. We harvested mesenteric, lumber, and inguinal lymph
nodes and thymus from iKrAP; αSMA-TK- and iKrAP; αSMA-TK+ mice to measure
GFP+ cancer cells by FACS. We found that iKrAP; αSMA-TK+ displayed increased
GFP+ cancer cell number in lymph nodes and thymus (Figure 13).

Depletion of αSMA+ myofibroblasts increased metastasis to pericolonic and perirectal fat
Pericolonic tumor deposits (PTDs) are metastatic adenocarcinoma nodules occurring in
the pericolonic and perirectal fat. PTDs are an independent prognostic factor for
advanced CRCs, and a destructive type of venous invasion different from other types of
vessel involvement. Many studies showed that the presence of PTDs correlated with
shorter overall survival in patients with stages III and IV CRCs [143]. Therefore, we
investigated whether depletion of αSMA+ myofibroblast increased dissemination of
cancer cells to pericolonic and perirectal fat. Interestingly, depleted animals exhibited the
remarkable inflammation of pericolonic fat, and histopathological analysis revealed that
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these inflammation lesions contained adipocytes, immune cells, vasculature, and cancer
cells (Figure 14A). To confirm histopathological analysis, we performed FACS, and we
found increased infiltration of cancer cells and immune cell population in depleted
tumors (Figure 14B).
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Figure 12. iKrAP; αSMA-TK showed increased invasion of cancer cells to lymphatic
vessels. Tumor sections from iKrAP; αSMA-TK- and iKrAP; αSMA-TK+ mice were
immunohistochemically stained with Β-catenin and LYVE-1 to identify cancer cells and lymphatic
vessels, respectively. Representative microscopic images and corresponding quantification (n=7;
iKrAP; αSMA-TK-, n=6; iKrAP; αSMA-TK+, Student T-Test, ***p<0.001)
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Figure 13. iKrAP; αSMA-TK showed increased metastasis of cancer cells to the lymphatic
system. Mesenteric, lumber, and inguinal lymph nodes and thymus were harvested from iKrAP;
αSMA-TK- and iKrAP; αSMA-TK+ mice after GCV treatment. GFP+ cells were counted by FACS.
Representative FACS images and corresponding quantification (Student T-Test, *p<0.05)
(T-Test, *p<0.05)
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Figure 14. iKrAP; αSMA-TK showed increased metastasis of cancer cells to pericolonic
and perirectal fat. (A) Pericolonic and perirectal fat were harvested from iKrAP; αSMA-TK- and
iKrAP; αSMA-TK+ mice after GCV treatment. (B) GFP+ cells were counted by FACS. Single cells
suspension was stained with anti-CD3, anti-CD45, and anti-CD11b. Representative FACS
images and corresponding quantification (Student T-Test, *p<0.05)

Depletion of αSMA+ myofibroblasts induce collagen-rich stroma to promote cancer cell
invasion
ECM remodeling is tightly regulated during development in normal colon. Abnormal
ECM production can upregulate integrin signaling and thus can improve cell survival and
proliferation [104]. Increased collagen contents by LOX overexpression promote ERK
and PI3 kinase signaling in cancer cells [105]. The properties of ECM also play a
significant role in regulating both stem cell and cancer stem cells. Abnormal changes of
ECM disrupt cellular differentiation, resulting in loss of differentiation and increased
stem cell pool [106].
A Recent study showed that collagen-1 promotes mesenchymal gene expression and
stimulate tumor cell invasion and collagen-1 is the most enriched genes in recurrenceprone tumors in CRC [107].
Previous our findings revealed that ablation of αSMA+ myofibroblasts induced poorly
differentiated, more invasive and metastatic tumors. Therefore, it is impossible that
aberrant expression of collagen contents alters the behavior of cancer cells, aggressive
phenotype.
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To test this possibility, picrosirius red staining was performed and revealed that a
significant increase of collagen contents in αSMA+ myofibroblasts-depleted tumors
(Figure 15). Additionally, Tumor collagen I assayed by type 1 collagen immunostaining
was significantly increased αSMA+ myofibroblasts-depleted tumors (Figure 16).
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Figure 15. αSMA myofibroblasts-depleted tumors revealed increased collagen deposition.
Tumor sections from iKrAP; αSMA-TK- and iKrAP; αSMA-TK+ mice were immunohistochemically
stained with Sirius Red. Representative microscopic images and corresponding quantification
(n=4; iKrAP; αSMA-TK-, n=5; iKrAP; αSMA-TK+, Student T-Test, ****p<0.0001)
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Figure 16. αSMA myofibroblasts-depleted tumors displayed increased type I collagen.
Tumor sections from iKrAP; αSMA-TK- and iKrAP; αSMA-TK+ mice were immunohistochemically
stained with collagen I. Representative microscopic images and corresponding quantification
(n=4; iKrAP; αSMA-TK-, n=5; iKrAP; αSMA-TK+, Student T-Test, **p<0.01)
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Chapter 5: Depletion of αSMA+ myofibroblasts results in immunesuppressive microenvironment in CRC
Cancer cells interact with their surroundings for growth, invasion, and metastasis. The
tumor microenvironment is composed of a diverse range of cells including stroma cells
and immune cells. The immune system is capable of controlling and shaping tumors
through a process known as immunoediting; elimination, equilibrium, and escape [108].
Experimental evidence has shown that inflammation support tumor development and
growth [109], but the role of adaptive immune responses is still widely unclear based on
murine and human studies. Although the presence of high proportion of cytotoxic CD8 T
cells has been most associated with a better prognosis in CRC, the prognostic assessment
to infiltration of Foxp3+regulatory T cells (Tregs) has been controversial [110].
About the prognostic value of Foxp3+Tregs, low CD3+ T cells and Foxp3+ Tregs in stage
II and stage III CRC is associated with shorter patient survival [111]. Another study
investigated that the proportion of Foxp3+ Tregs in healthy colon versus tumor tissue and
found that high Foxp3+ Tregs proportion in tumor tissue was associated with improved
survival, whereas the high density of Foxp3+ Tregs in the normal colon was associated
worse prognosis [112].
Additionally, suppressive immune profiles with increased CD4+Foxp3+ Tregs and
decreased CD8+ cytotoxic T cells were observed in αSMA+ myofibroblasts-depleted
mouse pancreatic tumors [94].
To interrogate whether depletion of αSMA+ myofibroblasts leads to immunosuppressive
microenvironment, we performed FACS analysis. We noted that αSMA+ myofibroblastsdepleted tumors displayed increased percentage of CD4+ Foxp3+ Tregs leading to the

52

overall decrease in Teff/Treg ratio together with reduced percentage of CD8+ cytotoxic T
cells (Figure 17).

+

Figure 17. Targeting αSMA myofibroblasts exhibited immunosuppressive
microenvironment. Tumor tissues were harvested and digested with enzyme mixture including
collagen 8, dispase I, and DNase I. For surface staining, single cell suspension was stained with
anti CD3e, CD4, CD8, and CD45. For foxp3 staining, cells were fixed with Foxp3 staining kit and
staining with anti-Foxp3. (n=6; iKrAP; αSMA-TK-, n=6; iKrAP; αSMA-TK+, Student T-Test,
**p<0.01, *p<0.05)
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Chapter 5: Depletion of αSMA+ myofibroblasts results in increase of
cancer stem cells in CRC
Many emerging evidence suggests that a small subpopulation of cancer cells, termed
cancer stem cells (CSCs), are responsible for propagation and dissemination in a very
efficient manner [113]. Compared normal stem cells, CSCs show slow rate of cell
cycling responsible for resistance to treatment such as chemotherapy and radiotherapy
and recurrence [114, 115]. Also, CSCs have a critical feature to initiate new tumors for
metastatic colonization to the distal organ.
In CRC, gene expression array to human patient samples revealed that aggressive CRC is
enriched in intestinal stem cell gene expression including Lgr5 [116]. Also, there was a
significant increase in Lgr5 expression in patients at stages III and IV comparing to
stages I and II of CRC. The expression of Dclk1 was also elevated in advanced stages
[117].
Since pathological morphology of αSMA+ myofibroblasts-ablated tumor revealed more
undifferentiated tumors with enhanced invasiveness, we expected increased expression of
Lgr5 and Dclk1in cancer cells of the αSMA+ myofibroblasts-ablated tumor.

Targeting αSMA+ myofibroblasts increased LGR5+ cancer stem cell population
To investigate whether αSMA+ myofibroblasts depletion is associated with increased
Lgr5+ cancer stem cells in CRC, we decided to perform FACS analysis. As we expected,
tumors with αSMA+ myofibroblasts depletion revealed increased Lgr5 expression on
cancer cells (Figure 18).
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Figure 18. Targeting αSMA myofibroblasts resulted in the Lgr5+ cell among cancer cells.
Tumor tissues were harvested and digested with enzyme mixture including collagen 8, dispase I,
and DNase I. Single cell suspension were stained with anti Lgr5 and CD45. Representative FACS
images and corresponding quantification (n=5; iKrAP; αSMA-TK-, n=6; iKrAP; αSMA-TK+,
Student T-Test, *p<0.05)
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Assessment of Dclk1+ cells in colon cancer cells
Next, we tested whether depletion of αSMA+ myofibroblasts increases Dclk1+ cancer
stem cell population. Immunohistochemical analysis revealed that dramatic increased
Dclk1+ cancer stem cell population when we targeted αSMA+ myofibroblasts (Figure 19).

+

Figure 19. Targeting αSMA myofibroblasts led to increased expression of DCLK1 in
cancer cells. Tumor sections from iKrAP; αSMA-TK- and iKrAP; αSMA-TK+ mice were
immunohistochemically stained with CK20 and DCLK1. Representative microscopic images and
corresponding quantification (n=4; iKrAP; αSMA-TK-, n=4; iKrAP; αSMA-TK+, Student T-Test,
**p<0.01)
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Depletion of αSMA+ myofibroblasts caused to up-regulation of cancer stem cell
proliferation
Previous our observation indicated that ablation of αSMA+ myofibroblasts increased the
frequency of Lgr5+ or Dclk1+ cancer stem cell population in TME. To address molecular
mechanism regarding this phenotype, we performed RNA sequencing (RNA-seq). We
found that a significant enrichment of the signature genes in negative regulation of stem
cell proliferation in control tumors, including pleiotrophin (PTN), singles-type MMTV
integration site family member 5A (WNT5A), snail homolog 2 (SNAI2), fibulin 1
(FBLN1), and bone morphogenetic protein 4 (BMP4) (Figure 20). This result highlight
αSMA+ myofibroblasts play an essential role in regulation of cancer stem cell
proliferation.
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Figure 20. Ablation of αSMA myofibroblasts resulted in enrichment of negative regulation
of cancer stem cell proliferation in control tumor. (A) GSEA revealed significant enrichment of
gene signatures with negative regulation of stem cell proliferation. (B) Comparison of RNA
rawcount between control tumors and depleted tumors (n=3; iKrAP; αSMA-TK-, n=3; iKrAP;
αSMA-TK+, Student T-Test, *p<0.05)
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Chapter 6: Summary and Discussion
It is widely believed that CAFs contributes to tumor growth, invasion, and metastasis by
secreting various growth factors, ECM proteins, chemokines, and cytokines. These
cellular and extracellular components alter genetic and epigenetic features of cancer cells.
In this regard, several studies were reported that CAFs correlated with poor prognosis in
cancer patients. LOXL2 is highly expressed in CAFs, which associated with poor colon
cancer survival [118]. Expression of PDGF receptor on CAFs is associated with
metastasis and poor survival in CRC [119]. Our data demonstrate that ablation of αSMA+
myofibroblasts results in multiple effects likely leading to reduced survival. These results
indicated that αSMA+ myofibroblasts have a protective role in CRC.
Several studies have been proposed that myofibroblasts can be a putative target for
cancer therapy because of their pro-invasive activity in vitro culture and tumor xenograft
mouse model. Only when adding conditioned media from myofibroblast culture isolated
from surgical colon cancer fragments, colon cancer cells invaded collagen gel [141].
Coimplantation of colon cancer cells and myofibroblasts dramatically increased
invasiveness of colon cancer cells [80], [120]. We demonstrated that αSMA+
myofibroblasts-ablated tumors exhibited increased local invasion, lymphovascular
invasion, CTCs number, and lymph node metastasis. Additionally, the morphology of
αSMA+ myofibroblasts-ablated tumors was similar with non-polypoid tumors that are
relatively depressed and flat but have a high risk of local invasion regardless of size.
Therefore, we speculated that αSMA+ myofibroblasts served as the physical barrier to
prevent migration of cancer cells to blood and lymphatic vasculatures.
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One of our interesting findings is that depletion of αSMA+ myofibroblasts results in
remodeling of the ECM with increased collagen contents in TME. Many studies
suggested that αSMA+ myofibroblasts and type I collagen are associated with tumor
progression [121-123]. It is widely accepted that myofibroblasts mainly contribute to the
production of type I collagen in TME but recent studies demonstrated that cancer cells
and other stroma cells secrete Type I collagen [124] [142]. Also, fibroblasts such as
FAP+ , FSP1+, or vimentin+ subpopulation could compensate collagen deposits.
Myofibroblasts are also the primary source of ECM-degrading proteins including MMPs.
In these respects, we can postulate that cancer cells and other stroma cells may
compensate production of type I collagen or lack of MMP2 and MMP7 secreted by
αSMA+ myofibroblasts. This causes a reduction in the efficacy of degradation of collagen
contents in TME.
Another impact of αSMA+ myofibroblast depletion was the alteration of immune cell
infiltration. Although most of the studies elucidating tumor-promoting functions of CAFs
were driven by co-culture experiments, CAFs are considered as a facilitator of
immunosuppressive TME. CAFs stimulated IL-6 signaling pathway on dendritic cells to
inhibit maturation, resulting in T cell anergy [125]. CAFs isolated human non-small cell
lung cancer expressed PD-L1 and PD-L2 [126]. In vivo study, depletion of αSMA+
myofibroblasts led to immunosuppressive adaptive immunity with increased Foxp3+ Treg
infiltration in PDAC [94]. We demonstrated that T cell-mediated immune responses were
impaired when αSMA+ myofibroblasts were ablated. αSMA+ myofibroblast-depleted
tumors exhibited increased Foxp3+ Treg infiltration along with decreased recruitment of
CD8+ cytotoxic T cells. Also, tumor-expressing collagens can trigger an inhibitory
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signaling via leukocyte-associated Ig-like receptors (LAIRs) for inactivation of cytotoxic
NK cells [127]. This study supported that aberrant deposition of collagen contents
promoted immunosuppressive TME in αSMA+ myofibroblast-depleted tumors.
The most striking effect when αSMA+ myofibroblasts were depleted is increased
stemness in cancer cells. CAFs are considered as a putative regulator of cancer stem cells
because of major capability to secrete ECM proteins that interact ECM receptors to
acquire or maintain stem cell properties. CAFs may induce epithelial-mesenchymal
transition (EMT)-driven cancer stemness in prostate cancer via reciprocal interaction
between cancer cells and CAFs [128]. IGF1R signaling in cancer cells was activated in
the presence of CAFs that induce Nanog expression and promote stemness in non-small
cell lung cancer [129]. Our data showed that the proportion of cancer stem cell
population expressing Lgr5+ or Dclk1+ was increased in αSMA+ myofibroblast-depleted
tumors. RNA-seq data revealed that gene signatures associated with down-regulation of
stem cell proliferation were enriched in non-depleted tumors. Therefore, it is possible that
aberrant collagen deposition in αSMA+ myofibroblast-depleted tumors led to stem cell
overexpression and loss of differentiation.
In summary, our data demonstrated a protective role of αSMA+ myofibroblasts in CRC
and targeting αSMA+ myofibroblasts resulted in diminished survival with the aggressive
tumor, aberrant collagen deposit, accumulation of Foxp3+ Tregs, and increased cancer
stem cell population (Figure 21).
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Depletion of myofibroblasts in CRC

Reduced survival with limb paresis
Decreased extraluminal tumor burden

Increased intraluminal tumor burden

Increased invasion and metastasis

Aberrant collagen deposit

Induction of immunosuppression

Increased frequency of CSCs

Decreased gene expressions related to
inhibition of CSC proliferation

Figure 21. Summary. Our study reveals unknown functional role of myofibroblasts in
regulating T cell-meditated anti-tumor immunity and stemness features in colon cancer
cells
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